Review

Vitamin K Status in Chronic Kidney Disease

Kristin M. McCabe 1, Michael A. Adams 1 and Rachel M. Holden 2,*

1 Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, ON K7L 3V6, Canada; E-Mails: 5km12@queensu.ca (K.M.M.); adams@queensu.ca (R.M.H.)
2 Department of Medicine, Queen’s University, Kingston, ON K7L 3V6, Canada

* Author to whom correspondence should be addressed; E-Mail: holdenr@kgh.kari.net; Tel.: +1-613-533-3134; Fax: +1-613-533-3292.

Received: 11 July 2013; in revised form: 17 October 2013 / Accepted: 31 October 2013 / Published: 7 November 2013

Abstract: The purpose of this review is to summarize the research to date on vitamin K status in chronic kidney disease (CKD). This review includes a summary of the data available on vitamin K status in patients across the spectrum of CKD as well as the link between vitamin K deficiency in CKD and bone dynamics, including mineralization and demineralization, as well as ectopic mineralization. It also describes two current clinical trials that are underway evaluating vitamin K treatment in CKD patients. These data may inform future clinical practice in this population.

Keywords: vitamin K; chronic kidney disease; renal insufficiency; vitamin K-dependent proteins

1. Introduction

In 2004 it was estimated that over 19 million Americans [1] and over 2 million Canadians [2] had chronic kidney disease (CKD). Compared to the general population, patients with CKD are at marked increased risk for cardiovascular disease and bone fracture. Vitamin K is a composite term referring to a group of fat-soluble vitamins that function as a co-factor for the enzyme γ-glutamyl carboxylase (GGCX), which activates a number of vitamin K-dependent proteins (VKDPs) that are involved in proper hemostasis, as well as vascular, and bone health. We and others have demonstrated that there is a very high prevalence of vitamin K deficiency within the CKD population suggesting that this represents a population at risk for any biological consequences of poor vitamin K status [3–6].
Vitamin K exists naturally as vitamin K₁ (phylloquinone) and several forms of vitamin K₂ (menaquinones) which differ in length of the isoprenoid side chain (MK-4–MK-11) [7]. Vitamin K₁ is found in highest concentration in green leafy vegetables, whereas vitamin K₂ is found in high concentrations in Natto, a popular Japanese food, as well as in some fermented cheeses. Both vitamin K₁ and MK-4 are found in tissues. Vitamin K₁ is the major dietary form, whereas MK-4 is believed to be produced via endogenous conversion of K₁, MK-7 and MK-4 itself. Vitamin K₁ is present in a variety of tissues with the highest levels being found in the liver [8,9], where it is involved in the carboxylation of coagulation factors (e.g., prothrombin). MK-4 is also found ubiquitously but is found in high concentrations in extra-hepatic tissues including the vasculature and bone. MK-4 appears to be the major form involved in catalyzing the carboxylation of the calcium-binding proteins, matrix Gla protein (MGP) and osteocalcin (OC), which protect against vascular calcification and bone loss, respectively [10]. Accordingly, measurements of inactive or uncarboxylated VKDPs such as uncarboxylated prothrombin, (protein induced by vitamin K absence/antagonism II/PIVKA-II), uncarboxylated osteocalcin (ucOC), and de-phosphorylated uncarboxylated MGP (dp-ucMGP) are used as a functional measure of overall vitamin K status [7,11]. It has been reported that there are high levels of ucOC and dp-ucMGP across the spectrum of low GFR [11]. Therefore, vitamin K may represent a modifiable risk factor for both cardiovascular and bone disease in the CKD population and could represent an important therapeutic target.

2. Basic Science

It has been established that vitamin K plays a role in the inhibition of calcification in animal models [12]. In healthy rats, global antagonism of vitamin K with a supra-therapeutic dosage of warfarin led to vascular calcification [12]. Further, the use of dietary vitamin K supplementation prevented and, in some cases, reversed vascular calcification in this model [13,14]. We have recently reported that changing vitamin K status greatly altered vascular calcification in rats with CKD. In contrast to the earlier models utilizing supra-therapeutic warfarin in healthy rats, we demonstrated, in animals with CKD, that low levels of warfarin (generating an INR of between 2 and 3), without any vitamin K supplementation depleted tissue vitamin K concentrations and markedly increased the susceptibility of all vessels to vascular calcification [9]. However, a therapeutic dosage of warfarin did not induce vascular calcification in healthy rats, despite the marked depletion of tissue K within extrahepatic tissues, suggesting that vitamin K status was critical only when CKD was also present. Further, high dietary vitamin K₁ significantly increased tissue vitamin K₁ concentrations and reduced the incidence and severity of vascular calcification in this CKD model [9]. These data indicate that, in the setting of experimental CKD, vitamin K status is an important regulator of vascular calcification [9].

3. Clinical Science

3.1. Vitamin K Status in Patients with CKD not yet Requiring Dialysis

Insufficient vitamin K availability leads to a decrease in the carboxylation of vitamin K dependent proteins including prothrombin, osteocalcin (OC), and matrix gla protein (MGP) in addition to low levels of circulating phylloquinone (<0.4 nM). Two studies have addressed the vitamin K status of
patients with CKD not yet requiring dialysis. We demonstrated in a study of 172 stage 3 to 5 CKD patients, most of whom were well-nourished, that over 50% consumed less than the recommended Adequate Intake (AI) for vitamin K [15]. Further, 6% were vitamin K insufficient according to low levels of serum phylloquinone (<0.4 ng/mL), 60% were insufficient according to high levels of ucOC (>20% ucOC), and 97% were insufficient according to high levels of PIVKA-II (>2 nmol/L) [15]. In this study, lower dietary intake of vitamin K predicted lower levels of phylloquinone and higher levels of PIVKA-II [15]. Schurgers et al., measured dephosphorylated, uncarboxylated MGP (dp-ucMGP) in a cohort of 107 patients ranging from CKD stages 2-5D, and reported that levels of plasma dp-ucMGP increased progressively with CKD stage, indicating a decline in this biomarker with a reduction in GFR [11]. These two studies confirm that patients with early stage CKD, including those who are well-nourished, are at risk for subclinical vitamin K deficiency; the degree to which biomarkers of vitamin K status change in response to supplementation with either vitamin K1 or vitamin K2 in early stage CKD has not been studied.

3.2. Vitamin K Status in Patients with CKD Receiving Hemodialysis (HD)

Studies have consistently demonstrated that there is a very high prevalence of sub-clinical vitamin K deficiency in patients requiring HD [3–6]. Due to its lipophilic characteristics, vitamin K would not be expected to be removed via the dialysis procedure. It is only recently that dietary intake of vitamin K was formally assessed in a cohort of HD patients [6]. In a study of 40 maintenance HD patients, dietary intake of vitamin K1 and K2 was below the values reported in healthy European reference populations and intake of both forms was particularly low on HD treatment days [6]. While the exact reason for the low intake is unknown, it is likely related to the dietary regimen prescribed for HD patients and overall poor nutrient intake. In addition, plasma levels of dp-ucMGP were elevated above the range reported in healthy people in all patients and 82.5% had elevated PIVKA-II [6]. However, the levels of these functional biomarkers of vitamin K status did not correlate with the measured dietary vitamin K intake in this small group of patients. Older studies performed in maintenance HD patients suggest that genetic variation (e.g., apolipoprotein E genotype) may be one important contributor [16].

In the Cranenburg study, and in one other large study of maintenance HD patients, levels of dp-ucMGP correlated with PIVKA-II levels suggesting a global vitamin K deficiency in HD patients in the arterial wall and liver respectively [6,17]. We have reported that 29% and 93% of maintenance HD patients met criteria for sub-clinical vitamin K deficiency based on low levels of phylloquinone and high levels of ucOC respectively [3] suggesting there is also vitamin K deficiency at the level of bone. Taken together, there is a growing and consistent body of evidence supporting the notion that maintenance HD patients have a global poor vitamin K status.

One randomized controlled trial has evaluated the response of biomarkers of vitamin K status (dp-ucMGP, PIVKA-II and ucOC) to 3 doses of vitamin K2 (MK-7) administered over a period of 6 weeks [5]. This study confirmed that most HD patients have functional vitamin K deficiency at baseline and reported that vitamin K2 (MK-7) supplementation decreased dp-ucMGP and PIVKA-II levels. However, only at the highest dose did MK-7 impact upon the carboxylation status of OC. This study provides the first evidence that functional vitamin K deficiency can be treated with vitamin K.
supplementation in the maintenance HD population, although the doses of each form of vitamin K required to correct the problem are not established.

3.3. Vitamin K Status in Patients with CKD Receiving Peritoneal Dialysis (PD)

Dietary vitamin K intake in patients receiving PD has not been assessed. There have been two studies demonstrating that PD patients have a similar degree of vitamin K insufficiency as maintenance HD patients. In a recent study of 28 PD patients, 46% had vitamin K deficiency as measured by elevated PIVKA II levels (>2 nM/L) [18]. We demonstrated in a cross-sectional study of 21 PD patients that 24% of patients had vitamin K deficiency as assessed by serum K1 (<0.4 nM/L) and all patients had vitamin K deficiency as assessed by increased percentage of ucOC (>20% was the cut off for vitamin K deficiency, mean was 60%) [19]. PD is an independent and home-based kidney replacement therapy and therefore PD patients tend to be younger and have less co-morbidity then maintenance HD patients. However, maintaining adequate nutrition represents a significant limitation of PD therapy and it is possible that this group of patients is at equivalent, or possibly higher, risk among the CKD population.

3.4. Studies of Bone Metabolism and Fracture Risk

Osteocalcin is a vitamin K dependent protein secreted by osteoblasts and plays a key role in maintaining appropriate bone turnover. Conditions associated with deficiency of vitamin K may lead to an increase in bone fracture risk and treatment with vitamin K may prevent bone loss and reduce fracture risk [20]. Patients with CKD requiring dialysis have a 4-fold increased risk of hip fracture compared with the general population. The Dialysis Outcomes and Practice Patterns study conducted in 12 countries reported an incidence of 8.9 new hip fractures and 25.6 new fractures of any kind per 1000 patient-years among maintenance HD patients [21]. Kohlmeier et al., were the first to demonstrate an independent association between poor vitamin K status and risk of bone fracture in patients who had reached ESKD and who required hemodialysis [4]. More recently, Fusaro et al., conducted an observational study of 387 prevalent HD patients and, using spinal radiographs, determined that over 50% of prevalent hemodialysis patients have vertebral fractures [22]. In this study, vitamin K1 deficiency (defined as a phylloquinone level adjusted for serum triglycerides <0.21 ng/mL), was the strongest predictor for the presence of a vertebral fracture with an adjusted odds ratio approaching 3 [22]. A few small studies have evaluated the impact of vitamin K supplementation on biomarkers of bone status in CKD patients. Only one study has considered vitamin K1 supplementation. Phylloquinone (2 mg/day) did not change levels of parathyroid hormone (PTH) or bone-specific alkaline phosphatase (ALP) over 6 months of treatment in a small group of maintenance HD patients [23]. The impact of phylloquinone on the carboxylation status of OC has not been reported. Two studies evaluated the impact of vitamin K2. In a German study, 53 maintenance HD patients were randomized to 3 dosages of vitamin K2 (MK-7; 45 µg/day, 135 µg/day, and 360 µg/day) treatment for a period of 6 weeks [5]. Only the highest dosage of MK-7 (360 µg/day) resulted in a significant decrease in ucOC. The impact of MK-7 supplementation on other biomarkers of bone metabolism was not reported in this study. Sugimoto reported that vitamin K2 (MK-4; 45 mg/day) resulted in a reduction of bone-specific alkaline phosphatase (ALP) over a 12 month period in 8 stable PD patients [24]. Taken together, a high dose of
vitamin K$_2$ was found to have modest impact upon the level of circulating ucOC and other bone-related markers, but whether this translates to changes in bone density or a reduction in fracture risk in the CKD population was not studied.

By inhibiting the recycling of vitamin K, warfarin induces a vitamin K deficient state which results in the inhibition of vitamin K-dependent proteins. Fusaro et al., found that hemodialysis patients treated with warfarin for greater than 1 year had an increased risk of vertebral fractures compared to those not on warfarin [25].

3.5. Studies of Vascular Calcification

Observational Studies of CAC

The presence of coronary artery calcification (CAC) is associated with an increased risk of cardiovascular disease and mortality independent of other risk factors [26–28]. Patients with CKD are at markedly increased risk for CAC [29–31]. MGP, a key inhibitor of vascular calcification, is present in the arterial wall and is dependent on vitamin K for its activity. Insufficient vitamin K availability may lead to an increase in under-carboxylated, and therefore inactive, MGP. The risk of vascular calcification in individuals is presumed higher if the calcification-inhibitory effect of MGP is impaired.

Pre-clinical studies confirm an influence of a diminished vitamin K status (e.g., warfarin or low dietary K$_1$) on the severity of arterial calcification in rats with CKD that can be prevented by a diet enhanced with vitamin K$_1$ [9]. However, the impact of vitamin K status and the carboxylation status of MGP specifically, on calcification in patients with CKD has not been resolved. It has been found that total ucMGP levels are significantly lower in patients on dialysis compared to control subjects [22,32]. However, in addition to carboxylation, MGP must also be phosphorylated on three serine residues to be secreted and fully active [33]. Therefore, to address this issue, some studies have measured the de-phosphorylated ucMGP (dp-ucMPG) form and have found that it is increased in CKD [11] and dialysis patients [6]. Preliminary studies in humans with CKD demonstrated that dp-ucMGP levels rise progressively with the severity of CKD [11]. Further, the dp-ucMGP levels were independently associated with aortic calcification measured by abdominal CT as well as mortality over a median duration of follow-up of 846 days [11,32]. These studies support an influence of vitamin K status on calcification in this population. However, whether the carboxylation status of MGP in the circulation represents a surrogate marker for vascular calcification in CKD (i.e., higher ucMGP:cMGP ratio) cannot be determined from these studies. Westenfeld et al., have reported that levels of dp-ucMGP are sensitive to vitamin K$_2$ (e.g., MK-7) supplementation in maintenance HD patients [5]. Whether or not improved vitamin K status translates into a reduction in vascular calcification is still unknown.

Warfarin is a vitamin K antagonist and its use represents a model of vitamin K insufficiency. We have demonstrated that long-term treatment with a vitamin K antagonist, warfarin, is independently associated with greater severity of aortic valve calcification in maintenance HD patients [34]. In addition, warfarin has been anecdotally linked to calciphylaxis in HD patients. Despite these associations, and the established increased risk of bleeding linked to this drug in the setting of CKD, warfarin is still prescribed to approximately 20% of dialysis patients in North America [35].
4. Clinical Trials

There is randomized controlled evidence from the general population that supports a treatment effect of vitamin K on arterial calcification. Supplementation with daily phylloquinone (0.5 mg) slowed the progression of CAC over 3 years in healthy older adults with pre-existing CAC at baseline [36]. Similarly, in an earlier RCT, post-menopausal women who were randomized to receive a supplement containing 1 mg/day phylloquinone in addition to minerals and 320 IU vitamin D₃ had better carotid artery distensibility, compliance, and elasticity after three years, compared to women who received the mineral supplement alone or the mineral supplement with vitamin D₃ [37]. Both of these trials studied individuals who were not at any particular risk for sub-clinical vitamin K deficiency.

It is well established that patients with kidney failure have an increased risk for both vascular calcification and sub-clinical vitamin K deficiency; yet, to date, no trial has been completed that examines whether vitamin K supplementation prevents the progression of calcification in this population. However, two randomized, placebo-controlled trials in this patient population are currently in progress and registered with Clinicaltrials.gov. The European study (VitaVasK study) is randomizing prevalent hemodialysis patients to 5 mg of vitamin K₁ thrice weekly for 18 months. The Canadian study (iPACK-HD study) is randomizing incident hemodialysis patients (<6 months) to 10 mg of vitamin K₁ thrice weekly for 12 months.

5. Conclusions

It has been consistently demonstrated that patients with CKD as well as those on HD or PD have subclinical vitamin K deficiency, as indicated by reduced serum K₁, higher percentage of ucOC and higher dp-ucMGP, as well as increased levels of PIVKA-II. Therefore this is a patient group at risk for the many consequences of sub-clinical vitamin K deficiency including cardiovascular disease and bone fracture, and vitamin K status may be a modifiable risk factor for these outcomes. Biomarkers of vitamin K status appear sensitive to supplementation in this population. These data, and the results of two clinical trials in progress, may inform clinical practice in the future.

Acknowledgments

The authors acknowledge the financial support provided by the Heart & Stroke Foundation of Ontario and the Kidney Foundation of Canada.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Coresh, J.; Selvin, E.; Stevens, L.A.; Manzi, J.; Kusek, J.W.; Eggers, P.; van Lente, F.; Levey, A.S. Prevalence of chronic kidney disease in the United States. *JAMA* **2007**, *298*, 2038–2047.
2. Levin, A.; Hemmelgarn, B.; Culleton, B.; Tobe, S.; McFarlane, P.; Ruzicka, M.; Burns, K.; Manns, B.; White, C.; Madore, F.; *et al.* Guidelines for the management of chronic kidney disease. *Can. Med. Assoc. J.* **2008**, *179*, 1154–1162.
3. Pilkey, R.M.; Morton, A.R.; Boffa, M.B.; Noordhof, C.; Day, A.G.; Su, Y.; Miller, L.M.; Koschinsky, M.L.; Booth, S.L. Subclinical vitamin K deficiency in hemodialysis patients. *Am. J. Kidney Dis.* 2007, 49, 432–439.

4. Kohlmeier, M.; Saupe, J.; Shearer, M.J.; Schaefer, K.; Asmus, G. Bone health of adult hemodialysis patients is related to vitamin K status. *Kidney Int.* 1997, 51, 1218–1221.

5. Westenfeld, R.; Krueger, T.; Schlieper, G.; Cranenburg, E.C.; Magdeleyns, E.J.; Heidenreich, S.; Holzmann, S.; Vermeer, C.; Jahnen-Dechent, W.; Ketteler, M.; et al. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. *Am. J. Kidney Dis.* 2012, 59, 186–195.

6. Cranenburg, E.C.; Schurgers, L.J.; Uiterwijk, H.H.; Beulens, J.W.; Dalmeijer, G.W.; Westerhuis, R.; Magdeleyns, E.J.; Herfs, M.; Vermeer, C.; Laverman, G.D. Vitamin K intake and status are low in hemodialysis patients. *Kidney Int.* 2012, 82, 605–610.

7. Booth, S.L.; Al Rajabi, A. Determinants of vitamin K status in humans. *Vitamins and Hormones* 2008, 78, 1–22.

8. Thijsen, H.H.; Drittij-Reijnders, M.J. Vitamin K distribution in rat tissues: Dietary phylloquinone is a source of tissue menaquinone-4. *Br. J. Nutr.* 1994, 72, 415–425.

9. McCabe, K.; Booth, S.; Fu, X.; Shobeiri, N.; Pang, J.; Adams, M.; Holden, R. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. *Kidney Int.* 2013, 83, 835–844.

10. Krueger, T.; Westenfeld, R.; Ketteler, M.; Schurgers, L.J.; Floege, J. Vitamin K deficiency in ckd patients: a modifiable risk factor for vascular calcification? *Kidney Int.* 2009, 76, 18–22.

11. Schurgers, L.J.; Barreto, D.V.; Barreto, F.C.; Liabeuf, S.; Renard, C.; Magdeleyns, E.J.; Vermeer, C.; Choukroun, G.; Massy, Z.A. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: A preliminary report. *Clin. J. Am. Soc. Nephrol.* 2010, 5, 568–575.

12. Price, P.A.; Faus, S.A.; Williamson, M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. *Arterioscler. Thromb. Vasc. Biol.* 1998, 18, 1400–1407.

13. Schurgers, L.J.; Spronk, H.M.; Soute, B.A.; Schieffers, P.M.; DeMey, J.G.; Vermeer, C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. *Blood* 2007, 109, 2823–2831.

14. Spronk, H.M.; Soute, B.A.; Schurgers, L.J.; Thijsen, H.H.; De Mey, J.G.; Vermeer, C. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. *J. Vasc. Res.* 2003, 40, 531–537.

15. Holden, R.M.; Morton, A.R.; Garland, J.S.; Pavlov, A.; Day, A.G.; Booth, S.L. Vitamins K and D status in stages 3–5 chronic kidney disease. *Clin. J. Am. Soc. Nephrol.* 2010, 5, 590–597.

16. Kohlmeier, M.; Saupe, J.; Drossel, H.J.; Shearer, M.J. Variation of Phylloquinone (Vitamin K1) concentrations in hemodialysis patients. *Thromb. Haemostasis* 1995, 74, 1252–1254.

17. Schlieper, G.; Westenfeld, R.; Krueger, T.; Cranenburg, E.C.; Magdeleyns, E.J.; Brandenburg, V.M.; Djuric, Z.; Damjanovic, T.; Ketteler, M.; Vermeer, C.; et al. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. *J. Am. Soc. Nephrol.* 2011, 22, 387–395.
18. Stankowiak-Kulpa, H.; Krzyzanowska, P.; Koziol, L.; Grzymislawski, M.; Wanik-Kossowska, M.; Moczko, J.; Walkowiak, J. Vitamin K status in peritoneally dialyzed patients with chronic kidney disease. *Acta Biochim. Pol.* 2011, 58, 617–620.

19. Holden, R.M.; Iliescu, E.; Morton, A.R.; Booth, S.L. Vitamin K status of canadian peritoneal dialysis patients. *Perit. Dial. Int.* 2008, 28, 415–418.

20. Fusaro, M.; Crepaldi, G.; Maggi, S.; Galli, F.; D’Angelo, A.; Calo, L.; Giannini, S.; Miozzo, D.; Gallieni, M. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: An important but poorly studied relationship. *J. Endocrinol. Investig.* 2011, 34, 317–323.

21. Jadoul, M.; Albert, J.M.; Akiba, T.; Akizawa, T.; Arab, L.; Bragg-Gresham, J.L.; Mason, N.; Prutz, K.G.; Young, E.W.; Pisoni, R.L. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. *Kidney Int.* 2006, 70, 1358–1366.

22. Fusaro, M.; Noale, M.; Viola, V.; Galli, F.; Tripepi, G.; Vajente, N.; Plebani, M.; Zaninotto, M.; Guglielmi, G.; Miotto, D.; et al. Vitamin K Italian (VIKI) dialysis study investigators. Vitamin K, vertebral fractures, vascular calcifications, and mortality: Vitamin K Italian (VIKI) dialysis study. *J. Bone Miner. Res.* 2012, 27, 2271–2278.

23. Reichel, H. No effect of vitamin k1 supplementation on biochemical bone markers in haemodialysis patients. *Nephrol. Dial. Transpl.* 1999, 14, 249–250.

24. Sugimoto, T.; Yamakado, M.; Matsushita, K.; Iwamoto, T.; Tagawa, H. Pharmacodynamics of menatetrenone and effects on bone metabolism in continuous ambulatory peritoneal dialysis patients. *J. Int. Med. Res.* 2002, 30, 566–575.

25. Fusaro, M.; Tripepi, G.; Noale, M.; Plebani, M.; Zaninotto, M.; Piccoli, A.; Naso, A.; Miozzo, D.; Giannini, S.; Avolio, M.; et al. Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients. *Curr. Vasc. Pharmacol.* 2013, in press.

26. Detrano, R.; Guerci, A.D.; Carr, J.J.; Bild, D.E.; Burke, G.; Folsom, A.R.; Liu, K.; Shea, S.; Szko, M.; Bluemke, D.A.; et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. *N. Engl. J. Med.* 2008, 358, 1336–1345.

27. Thompson, G.R.; Partridge, J. Coronary calcification score: The coronary-risk impact factor. *Lancet* 2004, 363, 557–559.

28. Vliegenthart, R.; Oudkerk, M.; Hofman, A.; Oei, H.H.; van Dijk, W.; van Rooij, F.J.; Witteman, J.C. Coronary calcification improves cardiovascular risk prediction in the elderly. *Circulation* 2005, 112, 572–577.

29. Coylewright, M.; Rice, K.; Budoff, M.J.; Blumenthal, R.S.; Greenland, P.; Kronmal, R.; Barr, R.G.; Burke, G.L.; Tracy, R.; Post, W.S. Differentiation of severe coronary artery calcification in the multi-ethnic study of atherosclerosis. *Atherosclerosis* 2011, 219, 616–622.

30. Qunibi, W.Y. Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. *J. Am. Soc. Nephrol.* 2005, 16, S95–S102.

31. Goodman, W.G.; Goldin, J.; Kuizon, B.D.; Yoon, C.; Gales, B.; Sider, D.; Wang, Y.; Chung, J.; Emerick, A.; Greaser, L.; et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N. Engl. J. Med.* 2000, 342, 1478–1483.
32. Cranenburg, E.C.; Brandenburg, V.M.; Vermeer, C.; Stenger, M.; Muhlenbruch, G.; Mahnken, A.H.; Gladziwa, U.; Ketteler, M.; Schurgers, L.J. Uncarboxylated matrix gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. *Thromb. Haemostasis 2009, 101*, 359–366.

33. Schurgers, L.J.; Spronk, H.M.; Skepper, J.N.; Hackeng, T.M.; Shanahan, C.M.; Vermeer, C.; Weissberg, P.L.; Proudfoot, D. Post-translational modifications regulate matrix gla protein function: Importance for inhibition of vascular smooth muscle cell calcification. *J. Thromb. Haemost. 2007, 5*, 2503–2511.

34. Holden, R.M.; Sanfilippo, A.S.; Hopman, W.M.; Zimmerman, D.; Garland, J.S.; Morton, A.R. Warfarin and aortic valve calcification in hemodialysis patients. *J. Nephrol. 2007, 20*, 417–422.

35. Wizemann, V.; Tong, L.; Satayathum, S.; Disney, A.; Akiba, T.; Fissell, R.B.; Kerr, P.G.; Young, E.W.; Robinson, B.M. Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. *Kidney Int. 2010, 77*, 1098–1106.

36. Shea, M.K.; O'Donnell, C.J.; Hoffmann, U.; Dallal, G.E.; Dawson-Hughes, B.; Or dovas, J.M.; Price, P.A.; Williamson, M.K.; Booth, S.L. Vitamin K supplementation and progression of coronary artery calcium in older men and women. *Am. J. Clin. Nutr. 2009, 89*, 1799–1807.

37. Braam, L.A.; Hoeks, A.P.; Brouns, F.; Hamulyak, K.; Gerichhausen, M.J.; Vermeer, C. Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: A follow-up study. *Thromb. Haemostasis 2004, 91*, 373–380.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).